Migration of Mouse-induced Pluripotent Stem Cells to Glioma-conditioned Medium is Mediated by Tumor-associated Specific Growth Factors

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Aug 7

PMID 22866078

Citations 15

Authors

Shinichiro Koizumi

Chunyu Gu

Shinji Amano

Seiji Yamamoto

Hayato Ihara

Tsutomu Tokuyama

Hiroki Namba

Affiliations

Soon will be listed here.

Abstract

Neural and mesenchymal stem cells have extensive tropism for malignant glioma. The tumor tropism of induced pluripotent stem (iPS) cells was tested using the Matrigel invasion assay. Mouse iPS cells showed a significant tropism to the conditioned media prepared from six rodent and human glioma cell lines and this tropism to the glioma conditioned media was partially blocked by the neutralizing antibodies for four major tumor-associated growth factors [stem cell factor (SCF), platelet-derived growth factor BB (PDGF-BB), stromal-derived factor-1α (SDF-1α) and vascular endothelial growth factor (VEGF)], which are secreted from the malignant gliomas. The tropism of the iPS cells was enhanced by the growth factors in a concentration-dependent manner from 0.1 to 100 ng/ml. The receptors for those growth factors (c-Kit, ICAM-1, CXCR4 and VEGFR2), measured by reverse transcriptase-polymerase chain reaction, were highly up-regulated in the mouse iPS cells compared to the mouse fibroblasts. The results showed that the specific growth factors secreted from the gliomas strongly attracted the iPS cells. Therefore, gene therapies using iPS cells as vectors to deliver anti-tumor agents are novel strategies for the treatment of malignant gliomas that deeply infiltrate the brain.

Citing Articles

Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity.

Nehama D, Woodell A, Maingi S, Hingtgen S, Dotti G Neuro Oncol. 2023; 25(9):1551-1562.

PMID: 37179459 PMC: 10484163. DOI: 10.1093/neuonc/noad092.

A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes.

Li Y, Tian L, Zhao T, Zhang J Cancer Immunol Immunother. 2023; 72(6):1673-1683.

PMID: 36622422 PMC: 10992126. DOI: 10.1007/s00262-022-03355-6.

Efficacy of HSV-TK/GCV system suicide gene therapy using SHED expressing modified HSV-TK against lung cancer brain metastases.

Oishi T, Ito M, Koizumi S, Horikawa M, Yamamoto T, Yamagishi S Mol Ther Methods Clin Dev. 2022; 26:253-265.

PMID: 35892087 PMC: 9307584. DOI: 10.1016/j.omtm.2022.07.001.

Molecular Mechanisms and Clinical Challenges of Glioma Invasion.

Oishi T, Koizumi S, Kurozumi K Brain Sci. 2022; 12(2).

PMID: 35204054 PMC: 8870089. DOI: 10.3390/brainsci12020291.

Intravenously Infused Stem Cells for Cancer Treatment.

Mercer-Smith A, Findlay I, Bomba H, Hingtgen S Stem Cell Rev Rep. 2021; 17(6):2025-2041.

PMID: 34138421 PMC: 8602714. DOI: 10.1007/s12015-021-10192-0.

References

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

Li S, Gao Y, Tokuyama T, Yamamoto J, Yokota N, Yamamoto S . Genetically engineered neural stem cells migrate and suppress glioma cell growth at distant intracranial sites. Cancer Lett. 2007; 251(2):220-7. DOI: 10.1016/j.canlet.2006.11.024. View

Koch P, Kokaia Z, Lindvall O, Brustle O . Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling. Lancet Neurol. 2009; 8(9):819-29. DOI: 10.1016/S1474-4422(09)70202-9. View

Michotte A, Neyns B, Chaskis C, Sadones J, In t Veld P . Neuropathological and molecular aspects of low-grade and high-grade gliomas. Acta Neurol Belg. 2005; 104(4):148-53. View

Serfozo P, Schlarman M, Pierret C, Maria B, Kirk M . Selective migration of neuralized embryonic stem cells to stem cell factor and media conditioned by glioma cell lines. Cancer Cell Int. 2006; 6:1. PMC: 1397869. DOI: 10.1186/1475-2867-6-1. View

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

Mentlein R, Held-Feindt J . Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J Neurochem. 2002; 83(4):747-53. DOI: 10.1046/j.1471-4159.2002.01179.x. View

Li S, Tokuyama T, Yamamoto J, Koide M, Yokota N, Namba H . Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther. 2005; 12(7):600-7. DOI: 10.1038/sj.cgt.7700826. View

Kim S, Cargioli T, Machluf M, Yang W, Sun Y, Al-Hashem R . PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin Cancer Res. 2005; 11(16):5965-70. DOI: 10.1158/1078-0432.CCR-05-0371. View

10.

Heese O, Disko A, Zirkel D, Westphal M, Lamszus K . Neural stem cell migration toward gliomas in vitro. Neuro Oncol. 2005; 7(4):476-84. PMC: 1871728. DOI: 10.1215/S1152851704000754. View

11.

Sasportas L, Kasmieh R, Wakimoto H, Hingtgen S, van de Water J, Mohapatra G . Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009; 106(12):4822-7. PMC: 2660771. DOI: 10.1073/pnas.0806647106. View

12.

Teicher B . Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev. 2002; 20(1-2):133-43. DOI: 10.1023/a:1013177011767. View

13.

Cheng P, Gao Z, Liu Y, Xue Y . Platelet-derived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1. Neurosci Lett. 2009; 451(1):52-6. DOI: 10.1016/j.neulet.2008.12.044. View

14.

Kim S, Kim S, Park I, Bang J, Aboody K, Wang K . Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res. 2006; 12(18):5550-6. DOI: 10.1158/1078-0432.CCR-05-2508. View

15.

Li S, Tokuyama T, Yamamoto J, Koide M, Yokota N, Namba H . Potent bystander effect in suicide gene therapy using neural stem cells transduced with herpes simplex virus thymidine kinase gene. Oncology. 2006; 69(6):503-8. DOI: 10.1159/000091032. View

16.

Aboody K, Brown A, Rainov N, Bower K, Liu S, Yang W . Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000; 97(23):12846-51. PMC: 18852. DOI: 10.1073/pnas.97.23.12846. View

17.

Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K . Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol. 2009; 27(8):743-5. DOI: 10.1038/nbt.1554. View

18.

Lee D, Ahn Y, Kim S, Wang K, Cho B, Phi J . Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res. 2009; 15(15):4925-34. DOI: 10.1158/1078-0432.CCR-08-3076. View

19.

DeAngelis L . Brain tumors. N Engl J Med. 2001; 344(2):114-23. DOI: 10.1056/NEJM200101113440207. View

20.

Ehtesham M, Yuan X, Kabos P, Chung N, Liu G, Akasaki Y . Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia. 2004; 6(3):287-93. PMC: 1502097. DOI: 10.1593/neo.3427. View